AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28150850
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral 180 mg ticagrelor
Trial: 24222836
Drug: Eptifibatide infusion
RxNorm normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eptifibatide infusion <10 hours
Trial: 24222836
Drug: Eptifibatide infusion
RxNorm normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eptifibatide infusion 10-17 hours
Trial: 24222836
Drug: Eptifibatide per-protocol
RxNorm normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eptifibatide per-protocol infusion (18-24 hours)
Trial: 15258349
Drug: Aspirin (100-325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100-325 mg/d)
Trial: 11419768
Drug: Diabetes recall
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetes recall system established at eight of the 21 sites, staff training in basic diabetes care, regular phone calls from the project officer, a two‐monthly newsletter and a mid‐project workshop.
Trial: 9438089
Drug: Saline containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline containing a low dose of epinephrine (50 ml, diluted to 1:200,000) with drain clamping for 20 hours
Trial: 9438089
Drug: Saline only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline only (50 ml) with drain clamping for 20 hours
Trial: 3435365
Drug: Ibuprofen 400mg
RxNorm normalized name: IBUPROFEN 400MG TAB
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 400mg tablet at the first sign of pain or bleeding, followed by 400mg every 4 to 6 hours for the duration of expected symptoms
Trial: 26200403
Drug: Control (Enoxaparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Enoxaparin Monotherapy)
Trial: 23306362
Drug: Prototype vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prototype vaccine containing LCTBA and CFA/I overexpressing E. coli
Trial: 23306362
Drug: Prototype vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prototype vaccine (higher dose)
Trial: 23306362
Drug: Reference vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference vaccine (CTB and inactivated wild type ETEC bacteria expressing CFA/I)
Trial: 21688030
Drug: HHD group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HHD group (4% succinylated gelatin infused at 20 ml•kg(‐1)BW•h(‐1) with targeted hematocrit of 30)
Trial: 12640221
Drug: Risperidone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (0.5 mg/day, increased up to 2.0 mg/day based on response)
Trial: 7862905
Drug: Fluoxetine (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (n = 22)
Trial: 1233188
Drug: Depot heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depot heparin (Calciparin)
Trial: 15105387
Drug: Electro-acupuncture (EA)
RxNorm normalized name: ELECTRODE SPRAY,ELECTRO MIST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electro-acupuncture (EA) in combination with a paracervical block (PCB) (n = 100)
Trial: 15105387
Drug: Conventional medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional medical analgesia (CMA) in combination with a PCB (n = 100)
Trial: 7717792
Drug: Structured sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured sleep hygiene with early morning light therapy
Trial: 1781822
Drug: Nonionic agents
RxNorm normalized name: LANOLIN DERIVATES,NONIONIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonionic agents (ioxaglate, iohexol)
Trial: 1781822
Drug: Ionic agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ionic agent (Renografin‐76)
Trial: 24153331
Drug: Intervention (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention (not specified in detail, but implied to be treatment for JCCP)
Trial: 15234049
Drug: Beta-irradiation (beta-RT)
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-irradiation (beta-RT) with (90)Sr, delivered 2500 cGy to the sclera surface at a dose rate of 200-250 cGy/min
Trial: 2902671
Drug: broxaterol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: broxaterol (0.5 mg)
Trial: 2902671
Drug: procaterol (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: procaterol (0.05 mg)
Trial: 28393317
Drug: MS medication
RxNorm normalized name: MS-1819
DrugBank: MS-1819 (DB15004)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MS medication video (attention control)
Trial: 26224613
Drug: Betamethasone injections
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone injections
Trial: 21402616
Drug: lesogaberan (65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lesogaberan (65 mg twice daily)
Trial: 18504447
Drug: High-flavanol cocoa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flavanol cocoa (HF, 902 mg flavanols)
Trial: 18504447
Drug: Low-flavanol cocoa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-flavanol cocoa (LF, 36 mg flavanols)
Trial: 17038680
Drug: Primaquine 45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primaquine 45 mg total dose (15 mg/day)
Trial: 17038680
Drug: Primaquine 105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primaquine 105 mg total dose (15 mg/day)
Trial: 17038680
Drug: Primaquine 210
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primaquine 210 mg total dose (15 mg/day)
Trial: 9363045
Drug: Low-dosage abecarnil
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dosage abecarnil (3.0-7.0 mg daily)
Trial: 9363045
Drug: High-dosage abecarnil
RxNorm normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dosage abecarnil (7.5-17.5 mg daily)
Trial: 1491390
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no remittive agents)
Trial: 4006379
Drug: Uniphyl (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uniphyl (two 400 mg tablets) under fasting conditions
Trial: 31686742
Drug: Isosorbide Mononitrate
RxNorm normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide Mononitrate (ISMN) 20 mg/day
Trial: 27669731
Drug: Individual Managing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual Managing Anger Program (I-MAP), a Cognitive behavioural therapy (CBT) and mindfulness-based anger management intervention
Trial: 11940031
Drug: Functional Electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Functional Electrical Therapy (FET) - 30 min daily sessions for 3 weeks
Trial: 11940031
Drug: Functional Electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Functional Electrical Therapy (FET) - LFG
Trial: 8592993
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 100 mg
Trial: 8592993
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 200 mg
Trial: 8592993
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 400 mg
Trial: 8592993
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 600 mg
Trial: 8592993
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of 300 mg twice daily for 6.5 days
Trial: 8592993
Drug: Concurrent administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent administration of probenecid
Trial: 2913960
Drug: Topical methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical methotrexate 0.1%
Trial: 2913960
Drug: Topical methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical methotrexate 0.5%
Trial: 2913960
Drug: Topical methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical methotrexate 1%
Trial: 30742522
Drug: 25% urea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% urea cream
Trial: 25002178
Drug: Bivalirudin (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin (bolus 0.75 mg/kg; infusion 1.75 mg/kg per hour)
Trial: 25002178
Drug: Heparin (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (70 U/kg)
Trial: 18469248
Drug: Turmeric supplementation
RxNorm normalized name: Turmeric
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turmeric supplementation (55 mg oxalate/d for 4 weeks)
Trial: 18469248
Drug: Cinnamon supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnamon supplementation (55 mg oxalate/d for 4 weeks)
Trial: 18469248
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (water only)
Trial: 16531835
Drug: Medical Symptom
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical Symptom Validity Test (MSVT) administered to IME patients
Trial: 10437188
Drug: Compound Tong
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Tong Jiang Oral Liquid with Da Huang (TJ)
Trial: 10437188
Drug: Qi Yin
RxNorm normalized name: San Qi Root
DrugBank: Panax notoginseng root (DB14304)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qi Yin Oral Liquid (QY)
Trial: 1441852
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy plus heparin (control)
Trial: 26280588
Drug: Polyaxial implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyaxial implants
Trial: 26280588
Drug: Monoaxial implant,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoaxial implant, cement-augmented, without laminectomy in patients 60 years or older
Trial: 24885354
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg dexamethasone before the first radiotherapy and three days placebo thereafter
Trial: 24885354
Drug: Four days
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four days 8 mg dexamethasone
Trial: 24885354
Drug: Daily placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily placebo for four days
Trial: 18343806
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination (lopinavir/ritonavir + zidovudine + lamivudine)
Trial: 12657404
Drug: Thiopental sodium
RxNorm normalized name: Thiopental Sodium
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiopental sodium 5 mg/kg (Group 1)
Trial: 12657404
Drug: Propofol 2
RxNorm normalized name: propofol 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2 mg/kg (Group 2)
Trial: 12657404
Drug: Etomidate 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate 0.3 mg/kg (Group 3)
Trial: 11253341
Drug: Immediate mobilization
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein, A, recombinant, stabilized / respiratory syncytial virus pre-fusion F protein, B, recombinant, stabilized Injection [Abrysvo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate mobilization and ambulation, external compression therapy, early Low Molecular Weight Heparin (LMWH) administration, and late oral anticoagulation.
Trial: 1286052
Drug: Needle stick
RxNorm normalized name: Zit Stick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needle stick (no injection)
Trial: 1286052
Drug: Saline with
RxNorm normalized name: CVS Saline with Aloe Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline with epinephrine (5 micrograms/ml)
Trial: 3084954
Drug: Reproterol infusion
RxNorm normalized name: reproterol
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reproterol infusion (0.2‐2.0 micrograms/kg/min in Saline)
Trial: 3084954
Drug: Salbutamol inhalation
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol inhalation (75 micrograms/kg in 2 ml Saline every two hours)
Trial: 3084954
Drug: Reproterol infusion
RxNorm normalized name: reproterol
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reproterol infusion (2.0 micrograms/kg/min)
Trial: 30125462
Drug: Everolimus with
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus with reduced tacrolimus (EVR/rTAC) and steroid elimination
Trial: 30125462
Drug: Standard tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard tacrolimus with mycophenolate mofetil (sTAC/MMF) and steroids
Trial: 27797674
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein with 66 mg of isoflavones (SPI)
Trial: 26001289
Drug: Lenalidomide (LEN)
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide (LEN) treatment
Trial: 19194127
Drug: Conventional carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Conventional carboplatin plus etoposide (CE) - carboplatin AUC 5 on day 1 IV and etoposide 140 mg/m IV on days 1-3, q28 days
Trial: 19194127
Drug: Dose-intensified carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose-intensified carboplatin plus etoposide plus lenograstim - carboplatin AUC 5 on day 1 IV and etoposide 190 mg/m days 1-3 IV with lenograstim 263 microg subcutaneously on days 4-13, q21 days
Trial: 15012621
Drug: Spironolactone plus
RxNorm normalized name: Spironolactone Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone plus finasteride (100 mg/day + 5 mg/day)
Trial: 15012621
Drug: Spironolactone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (100 mg/day) alone
Trial: 11879339
Drug: Monotherapy (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (400 mg CBZ per day)
Trial: 11879339
Drug: Polytherapy (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polytherapy (200 mg CBZ plus 300 mg VPA per day)
Trial: 8334827
Drug: Indomethacin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (1 mg kg‐1)
Trial: 8334827
Drug: Metoprolol (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (1.5 mg kg‐1)
Trial: 3595669
Drug: Regimen A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen A: procarbazine (100 mg/m2 p.o., max 150 mg) days 1-10, vindesine (3 mg/m2 i.v., max 5 mg) days 1 and 8, CCNU (150 mg/m2 p.o., max 200 mg) day 1
Trial: 3595669
Drug: Regimen B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen B: procarbazine (100 mg/m2 p.o., max 150 mg) days 1-10, DTIC (250 mg/m2 i.v. max 400 mg) days 1-5, CCNU (150 mg/m2 p.o. max 200 mg) day 1
Trial: 30232866
Drug: Thermosensitive moxibustion
RxNorm normalized name: BUTYLENE GLYCOL 0.2 g in 1 g CUTANEOUS TAPE [ShiZhenTaiYiTang Moxibustion Patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermosensitive moxibustion (TSM), applied to bilateral Taichong (LR 3) and Qiuxu (GB 40) once daily for 15 days.
Trial: 30232866
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (Estazolam tablets, 1 mg/d, once daily for 15 days).
Trial: 27058964
Drug: Single HA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single HA injection
Trial: 27058964
Drug: Double HA
RxNorm normalized name: HOUTTUYNIA CORDATA FLOWERING TOP 11.6 g in 100 mL / PERILLA FRUTESCENS LEAF 11.6 g in 100 mL TOPICAL LIQUID [Dr.Double Ha ULTRA SOOTHING ESSENCE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double HA injection
Trial: 7593728
Drug: Moclobemide and
RxNorm normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide and Fluoxetine
Trial: 2344514
Drug: Digital rectal
RxNorm normalized name: BD Thermometer Digital Rectal (obsolete)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital rectal examination by a urologist or general practitioner
Trial: 7026542
Drug: Phenelzine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenelzine (mean 81 mg/day)
Trial: 7026542
Drug: Imipramine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (mean 144 mg/day)
Trial: 30215460
Drug: Ultrasound-guided bilateral
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided bilateral TAP block using 40 mL 0.25% bupivacaine
Trial: 22823027
Drug: Continued protease
RxNorm normalized name: protease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued protease inhibitor (PI) or non-nucleoside reverse transcriptase inhibitor (NNRTI)
Trial: 12017948
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of fenticonazole nitrate intravaginal ovules
Trial: 12017948
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of myconazole vaginal ovules
Trial: 7776934
Drug: rhDNase (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhDNase (2.5 mg once daily)
Trial: 1983214
Drug: Topical oxatomide
RxNorm normalized name: oxatomide
DrugBank: Oxatomide (DB12877)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical oxatomide gel 5%
Trial: 28093837
Drug: Single-dose simulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose simulation education with structured debriefing and verbal feedback
Trial: 10365191
Drug: Interactional Treatment
RxNorm normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactional Treatment (IT)
Trial: 7495248
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation with 14 vitamins and 12 minerals at two to three times the US RDA
Trial: 1783363
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of amiloride (2 x 2.5 mg) and long‐acting furosemide (2 x 10 mg)
Trial: 1783363
Drug: Amiloride (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride (5 mg) and furosemide (20 mg)
Trial: 6813814
Drug: EPCC combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPCC combined with aspirin (300 mg bid) and dipyridamole (75 mg tid)
Trial: 31993943
Drug: Twice-daily cyclosporine
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily cyclosporine
Trial: 11811547
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (200 mg of D‐alpha‐tocopheryl acetate daily)
Trial: 11811547
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (500 mg of slow release ascorbate daily)
Trial: 7775548
Drug: Combined perioperative
RxNorm normalized name: ENSURE SURGERY PERIOPERATIVE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined perioperative infusion of nifedipine and metoprolol (NM)
Trial: 27025986
Drug: Oxycodone ER
RxNorm normalized name: oxycodone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone ER (Xtampza ER)
Trial: 18335118
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 20 ml of honey before and after radiation therapy
Trial: 18335118
Drug: Rinsing with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rinsing with 20 ml of saline before and after radiation therapy
Trial: 22383098
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg oral sildenafil
Trial: 14698783
Drug: [(99m)Tc]DTPA-mannosyl-dextran (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: [(99m)Tc]DTPA-mannosyl-dextran (all doses)
Trial: 10714909
Drug: 7-day-Estradiol patch
RxNorm normalized name: estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7-day-Estradiol patch (50 microg estradiol per day)
Trial: 9187443
Drug: Involved-field radiotherapy
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Involved-field radiotherapy (IF-RT) given to 90% of patients in partial remission (PR) after chemotherapy.
Trial: 9187443
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment for patients in complete remission (CR) after chemotherapy.